https://www.aigom.it/wp-content/uploads/2025/09/articolo9settembre.png1216849Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-09-09 07:56:122025-09-09 07:56:12TRASTUZUMAB DERUXTECAN (T-DXd)+PERTUZUMAB (P) vs TAXANE+TRASTUZUMAB+PERTUZUMAB (THP) FOR FIRST-LINE (1L) TREATMENT OF PATIENTS (pts) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) ADVANCED/METASTATIC BREAST CANCER (a/mBC): INTERIM RESULTS FROM DESTINY-BREAST09
https://www.aigom.it/wp-content/uploads/2025/09/ART2SETTEMBRE.png12881109Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-09-02 07:05:482025-09-02 07:05:48PERIOPERATIVE DURVALUMAB IN GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER.
https://www.aigom.it/wp-content/uploads/2025/07/ART15LUGLIO.png1315960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-07-14 07:49:272025-07-14 07:49:27ENCORAFENIB, CETUXIMAB, AND mFOLFOX6 IN BRAF-MUTATED COLORECTAL CANCER.
https://www.aigom.it/wp-content/uploads/2025/07/ART8LUGLIO.png1349960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-07-08 08:31:402025-07-08 08:31:40FRUQUINTINIB VERSUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2): AN INTETRNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY.
https://www.aigom.it/wp-content/uploads/2025/07/ART1LUGLIO.png1146960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-07-01 08:46:042025-07-01 08:46:04ELIZANENTANT FOR VASOMOTOR SYMPTOMS FROM ENDOCRINE THERAPY FOR BREAST CANCER
https://www.aigom.it/wp-content/uploads/2025/06/ART24.6.png1272888Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-06-23 08:16:072025-06-23 08:16:07ZOLBETUXIMAB PLUS mFOLFOX6 IN PATIENTS WITH CLDN18.2-positive, HER2-negative, UNTREATED, LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA (SPOTLIGHT): A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 TRIAL.
https://www.aigom.it/wp-content/uploads/2025/06/ART3.6.png1350960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-06-03 07:58:002025-06-03 07:58:00DATOPOTAMAB DERUXTECAN IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH ACTIONABLE GENOMIC ALTERATIONS: RESULTS FROM THE PHASE II TROPION-Lung05 STUDY.
https://www.aigom.it/wp-content/uploads/2025/05/ART27MAGGIO.png1411960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-27 08:00:382025-05-27 08:00:38PEMBROLIZUMAB AND CHEMOTHERAPY IN HIGH-RISK, EARLY-STAGE, ER+/HER2-BREAST CANCER: A RANDOMIZED PHASE 3 TRIAL.
https://www.aigom.it/wp-content/uploads/2025/05/ART20.5.png1254841Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-20 09:51:122025-05-20 09:51:12DIAGNOSIS AND MANAGEMENT OF INFECTIONS CAUSED BY MULTIDRUG-RESISTANT BACTERIA: GUIDELINE ENDORSED BY ITALIAN SOCIETY OF INFECTION AND TROPICAL DISEASES (SIMIT), THE ITALIAN SOCIETY OF ANTI-INFECTIVE THERAPY (SITA), THE ITALIAN GROUP FOR ANTIMICROBIAL STEWARDSHIP (GISA), THE ITALIAN ASSOCIATION OF CLINICAL MICROBIOLOGIST (AMCLI) AND THE ITALIAN SOCIETY OF MICROBIOLOGY (SIM).
